Xilio Therapeutics, Inc. disclosed that as of January 2, 2026, it has exercised 48,207,815 Series B warrants from a previous public offering, generating $35.8 million to support operations until mid-2027; also, 66,676,000 Series C warrants are now outstanding with potential additional proceeds of $36.2 million if exercised before year-end 2026.